Bochuang Biotechnology Secures Angel Funding for High-Purity Collagen and Innovative Medical Product Development
Jiangsu Bochuang Biotechnology Co., Ltd reportedly secured an undisclosed amount of funding in an angel...
NMPA Accepts Market Filing for Guangdong Zhongsheng’s COVID-19 Drug RAY1216
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that the market filing for...
Mabwell Bioscience’s 9MW3811 Gains NMPA Approval for Clinical Trials in China
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical...
Everest Medicines’ Xerava Receives NMPA Approval for Complicated Intra-Abdominal Infections
China-based Everest Medicines Limited (HKG: 1952) has announced that it has received market approval from...
Terumo Blood and Cell Technologies Partners with EurekaBio to Establish Cell Therapy Lab
US-based Terumo Blood and Cell Technologies has entered into a partnership with Shenzhen-headquartered EurekaBio Technology...
Beijing Initiates Volume-Based Procurement for Ophthalmology and Orthopedics Medical Consumables
The Beijing Municipal Medical Insurance Bureau has released a notification regarding the volume-based procurement (VBP)...
Fosun Pharma’s Generic Remodulin Gains NMPA Approval for Pulmonary Arterial Hypertension
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its generic...
RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor
China-based pharmaceutical firm RemeGen (HKG: 9995) has received approval from the National Medical Products Administration...
Triastek Partners with Boehringer Ingelheim to Advance 3D Printed Drug Dosage Forms
China-based Triastek Inc., a leading pharmaceutical-focused 3D printing company, has entered into a partnership with...
ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced that it has received approval from...
ArkBio and Calibr Renew Collaboration to Develop First-in-Class Respiratory Drug AK0705
Shanghai Ark Biopharmaceutical Co., Ltd announced that it has renewed its co-development collaboration with Calibr,...
Agena Bioscience’s CYP2C19 Genotyping Kit Gains NMPA Approval for Cardiovascular Applications
Shanghai-based Agena Bioscience announced that its human CYP2C19 genotyping test kit, co-developed with Simcere Pharmaceutical...
Ping An Life Insurance Reports Steady Profit Growth and Expands Managed Care Services
Ping An Life Insurance Company of China Ltd released its 2022 financial report, recording RMB...
Akeso Biopharma Reports 422% Increase in Product Sales, Boosted by Cadonilimab and Penpulimab
China-based Akeso Biopharma (HKG: 9926) released its 2022 financial report, highlighting significant growth in product...
CStone Pharmaceuticals Reports 97.54% Revenue Growth in 2022, Driven by Drug Sales and Licensing Fees
China-based CStone Pharmaceuticals (HKG: 2616) released its 2022 financial report, recording total revenues of RMB...
Henlius’ OX40 Monoclonal Antibody HLX51 Gains NMPA Approval for Phase I Clinical Study
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced that it has received approval from the...
Boao Lecheng and Shanghai Biomed Center Form Long-Term Partnership for Medical Innovation
The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has entered into a long-term...
Haisco Pharmaceutical’s EGFR-PROTAC HSK40118 Gains NMPA Approval for Clinical Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that it has received clinical...
Astellas Pharma’s Xtandi Gains Momentum in China with Positive Phase III ARCHES Study Results
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced that its prostate cancer therapy, Xtandi (enzalutamide),...
World Orphan Drug Alliance Expands to China with RareStone Group Partnership
The World Orphan Drug Alliance (WODA) has announced its expansion to China for the first...